Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes

Sponsor
Yanbing Li
Study ID
NCT07198932
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cofrogliptin add to insulin — DRUG
    Patients will be treated with commercially available cofrogliptin according to routine clinical practice at the discretion of the treating physician.
  • Linagliptin add to insulin — DRUG
    Patients will be treated with commercially available linagliptin according to routine clinical practice at the discretion of the treating physician.

Study Details

This study is a multicenter, prospective, non-interventional real-world study to evaluate the clinical outcomes of biweekly cofrogliptin versus daily linagliptin as an add-on therapy in Chinese adult T2D patients.

Key Dates

Start date
Oct 1, 2025
Status verified
Sep 2025
Primary completion
Jul 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
594 participants (estimated)

Arms

  • Arm: Cofrogliptin cohort
  • Arm: Linagliptin cohort

Primary Outcome Measure

Change in HbA1c [ Time Frame: from baseline to 24 weeks ]

Related Studies